Risk of Venous Thromboembolism With Tofacitinib Versus Tumor Necrosis Factor Inhibitors in Cardiovascular Risk-Enriched Rheumatoid Arthritis Patients.
Charles-Schoeman C, Fleischmann R, Mysler E, Greenwald M, Ytterberg SR, Koch GG, Bhatt DL, Wang C, Mikuls TR, Chen AS, Connell CA, Woolcott JC, Menon S, Chen Y, Lee K, Szekanecz Z.
Charles-Schoeman C, et al. Among authors: chen as.
Arthritis Rheumatol. 2024 Mar 13. doi: 10.1002/art.42846. Online ahead of print.
Arthritis Rheumatol. 2024.
PMID: 38481002